Venrock Healthcare Capital Partners III L.P. 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:48 pm Purchase | 2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN | Venrock Healthcare Capital Partners III L.P. | 4,026,331 8.500% | 1,071,429 (+36.26%) | Filing |
| 2024-02-14 8:53 pm Purchase | 2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN | Venrock Healthcare Capital Partners III L.P. | 2,954,902 7.200% | 740,760 (+33.46%) | Filing |
| 2023-03-13 4:01 pm Purchase | 2023-03-03 | 13G | Enliven Therapeutics, Inc. ELVN | Venrock Healthcare Capital Partners III L.P. | 2,214,142 5.400% | 2,214,142 (New Position) | Filing |